Axsome Therapeutics, Inc. · NASDAQ:AXSM
Axsome Therapeutics — Technical Presentation (May 2020)
15 slides from Axsome Therapeutics's technical presentation, May 2020
Slide 1: Efficacy and Safety of AXS-05 in Major Depressive Disorder: GEMINI Phase 3 Results
Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder Results From the GEMINI Phase 3, Double- Blind, Placebo-Controlled Trial ASCP 2020 Oral Session Cedric O’Gorman3, Amanda Jones3, Dan V. Iosifescu1,2, Herriot Tabuteau3 1NYU School o
Slide 2: Major Depressive Disorder (MDD): Need for New, Innovative Treatments
ASCP 2020 Major Depressive Disorder (MDD): Need for New, Innovative Treatments • Major depressive disorder (MDD) is a disabling and life-threatening, biologically-based disorder as a leading cause of suicide1,2 • 63% and 44% of MDD patients have inadequate response to initial therapy and second line
Slide 3: Glutamatergic Signaling in MDD: Potential Role for NMDA Blockade
ASCP 2020 Glutamatergic Signaling in MDD: Potential Role for NMDA Blockade • Clinical and preclinical evidence has implicated dysfunctional glutamatergic neurotransmission in the pathophysiology of MDD, suggesting a role for NMDA receptor antagonism in the treatment of MDD.1,2 • NMDA receptor blocka
Slide 4: AXS-05: Novel, Oral, NMDA Receptor Antagonist with Multimodal Activity
ASCP 2020 AXS-05: Novel, Oral, NMDA Receptor Antagonist with Multimodal Activity NMDA Receptor Modulation of Na+/Ca2+ Antagonism DM Delivery AXS-05 160 DM Plasma Concentration NMDA receptor AXS-05 DM component 80 of AXS-05 Mg2+ Cell DM membrane 0 0 12 24 36 Time K+ dextromethorphan/bupropion modulat
Slide 5: AXS-05 Clinical Program in MDD
ASCP 2020 AXS-05 Clinical Program in MDD MDD NDA-Enabling Efficacy Studies: Status: AXS-05 ASCEND Positive 1:1 (N=80) results Bupropion AXS-05 GEMINI Positive 1:1 (N=327) results Placebo Open Label Safety Study: AXS-05 1 6 months, N=300 1 year, N = 100 • Ongoing © Axsome Therapeutics, Inc. 5
Slide 6: GEMINI Trial of AXS-05 in MDD: Design Summary
ASCP 2020 GEMINI Trial of AXS-05 in MDD: Design Summary A Phase 3 trial to assess the efficacy and safety of AXS-05 in the treatment of MDD Double-blind Dosing Period (6 weeks) Week 0 Week 1 Week 2 Week 3 Week 4 Week 6 Up to 4-week Screening Period N = 327 N = 163 AXS-05 Subjects with (45 mg DM + 10
Slide 7: GEMINI Trial of AXS-05 in MDD: Key Entry Criteria
ASCP 2020 GEMINI Trial of AXS-05 in MDD: Key Entry Criteria Inclusion criteria included: • Male or female 18-65 years of age inclusive • DSM-5 criteria for current MDD without psychotic features • MADRS total score of ≥ 25 • CGI-S score of ≥ 4 at baseline Exclusion criteria included: • History of el
Slide 8: GEMINI Trial: Demographics and Baseline Characteristics
ASCP 2020 GEMINI Trial of AXS-05 in MDD: Demographics and Baseline Characteristics AXS-05 (45 mg DM / 105 mg BUP) Placebo Age (years) 42.1 (12.71) 41.1 (13.78) Female Gender, n (%) 98 (60.1%) 117 (71.3%) Race, n (%) White 88 (54.0%) 61 (37.4%) 92 (56.1%) Black or African American 55 (33.5%) Asian 9
Slide 9: Improvement in MADRS Total Score with AXS-05: Primary Endpoint
ASCP 2020 Improvement in MADRS Total Score with AXS-05: Primary Endpoint 0 AXS-05 (45 mg dextromethorphan / 105 mg bupropion BID) -2 Placebo -4 -6 Change from Baseline MADRS Total Score -8 P=0.007 -10 -12 P<0.001 -14 P<0.001 -16 -18 P<0.001 P=0.002 -20 Baseline 1 2 3 4 5 6 Week AXS-05 Placebo Differ
Slide 10: Rapid Achievement of Clinical Remission with AXS-05: MADRS ≤ 10
ASCP 2020 Rapid Achievement of Clinical Remission with AXS-05: MADRS ≤ 10 45% AXS-05 Placebo P<0.001 40% 40% 35% Achieving Remission (MADRS ≤ 10) P<0.001 30% 32% Percentage of Subjects P=0.002 25% 24% 20% P=0.013 15% 17% 17% 10% 12% 11% 5% 8% 3% 2% 0% 1 2 3 4 6 Week © Axsome Therapeutics, Inc. 10
Slide 11: Early and Sustained Clinical Response with AXS-05
ASCP 2020 Early and Sustained Clinical Response with AXS-05: (≥ 50% MADRS improvement) 60% P<0.001 AXS-05 Placebo P<0.001 54% 50% P=0.001 49% Percentage of Responders 40% 42% (≥ 50% MADRS) P=0.020 34% 30% 28% 27% 25% 20% P=0.035 17% 15% 10% 7% 0% 1 2 3 4 6 Week © Axsome Therapeutics, Inc. 11
Slide 12: Rapid and Durable Improvements: Global, Functional and Quality of Life Measures
ASCP 2020 Rapid and Durable Improvements: Global, Functional and Quality of Life Measures AXS-05 vs Placebo Week 1 Week 2 Week 6 Depressive Symptom Improvement CGI-I 22% vs 13% 44% vs. 22% 58% vs. 43% % with marked/moderate improvement p=0.035 p=<0.001 p=0.016 CGI-S 0.7 vs. 0.4 1.1 vs 0.7 1.7 vs. 1.
Slide 13: GEMINI Trial Results: Safety & Tolerability
ASCP 2020 GEMINI Trial Results: Safety & Tolerability AXS-05 Placebo (N = 162) (N = 164) Any Treatment-Emergent AE 100 (61.7%) 74 (45.1%) Dizziness 26 (16.0%) 10 (6.1%) Nausea 21 (13.0%) 14 (8.5%) Headache 13 (8.0%) 6 (3.7%) Diarrhea 11 (6.8%) 5 (3.0%) Somnolence 11 (6.8%) 5 (3.0%) Dry mouth 9 (5.6%
Slide 14: GEMINI Trial of AXS-05 in MDD: Conclusions
ASCP 2020 GEMINI Trial of AXS-05 in MDD: Conclusions • AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity, representing a potential mechanistically new approach for the treatment of depression • AXS-05 met the primary endpoint demonstrating statistically signi
Slide 15: Q&A
Q&A © Axsome Therapeutics, Inc. 15
Axsome Therapeutics — Technical Presentation (May 2020) on 6ix